Results for: DOI

Researchers at Johns Hopkins University have discovered that the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating specific neurons in the brain. The study, published in Neuron, reveals that DOI works by influencing parvalbumin-positive interneurons in the ventral hippocampus, leading to a decrease in anxiety-related activity. The findings suggest potential therapeutic benefits for anxiety disorders without the hallucinogenic effects commonly associated with psychedelics.

A crucial victory for psychedelic research advocates! A DEA administrative law judge has rejected the agency’s attempt to exclude crucial witnesses and evidence in an upcoming hearing challenging the DEA’s proposed ban on two psychedelic compounds, DOI and DOC. The judge’s decision is a major win for those who argue that the DEA’s proposed ban is unjustified and could severely hinder scientific exploration of the potential therapeutic benefits of these compounds.